© All rights reserved. Powered by YOOtheme.

Critical Care Reviews Newsletter

Newsletter 480  |  February 21st 2021

IL-6 Receptor Antagonist Domain Results Presentation - Thursday, February 25th

Welcome to the 480th Critical Care Reviews Newsletter, bringing you the best critical care research and open access articles from across the medical literature over the past seven days.

The highlights of this week's edition are a randomised controlled trial investigating vitamin D3 in patients with moderate to severe COVID-19; a systematic review and meta analysis on remdesivir and systemic corticosteroids for the treatment of COVID-19; and an observational study on prone positioning in mechanically ventilated patients with COVID-19-related respiratory failure. There are also guidelines on acute kidney injury in children & the nutritional management of the critically ill neonate; narrative reviews on renal dysfunction in cirrhosis & the intensive care management of patients with COVID-19; an editorial on prophylactic anticoagulation for patients in hospital with covid-19; and a commentary on trends in COVID-19-related in-hospital mortality: lessons learned from nationwide samples.

If you only have time to read one review article this week, try this one on pharmacological mechanisms of immunomodulatory agents for the treatment of severe cases of COVID-19 infection.

CCR Spring Series of Trial Results

The first of our Spring Series of major trial results starts this Thursday, February 25th, with the presentation of the full results of the REMAP-CAP IL-6 receptor antagonist domain. The timing isn't confirmed just yet, but, as usual, this will be a full, free livestream accessible on the Critical Care Reviews website, CCR Vimeo channel and on Twitter. Please watch the CCR homepage for further updates, including the full programme for the session. It's likely to take place in the evening / early night time UTC.

 

I hope you find this newsletter useful.


Until next week

Rob

 

 

Supported by the Health Research Board

 

 



© All rights reserved.

Back to Top